From: Genetic predisposition to male breast cancer in Poland
Gene | Mutation | All patients | Controla | Â | ||||||
---|---|---|---|---|---|---|---|---|---|---|
 |  | Positive | Total | % | Positive | Total | % | OR | 95%CI | p-value |
BRCA1 | c.5263_5264insC | 1 | 165 | 0.6% | 13 | 4000 | 0.32% | 1.87 | 0.24–14.38 | 0.54 |
c.181 T > G | 0 | 165 | 0.0% | 3 | 4000 | 0.08% | – | – |  | |
c.4035delA | 0 | 165 | 0.0% | 1 | 4000 | 0.03% | – | – |  | |
Any BRCA1 | 1 | 165 | 0.6% | 17 | 4000 | 0.42% | 1.43 | 0.19–10.80 | 0.73 | |
PALB2 | 509_510delGA | 4 | 165 | 2.4% | 7 | 4702 | 0.1% | 16.70 | 4.83–57.50 | < 0.001 |
172_175deITTGT | 0 | 165 | 0.0% | 3 | 4702 | 0.05% | – | – |  | |
Any PALB2 | 4 | 165 | 2.4% | 10 | 4702 | 0.15% | 11.66 | 3.62–37.57 | < 0.001 | |
CHEK2 | 1100delC | 3 | 165 | 1.8% | 12 | 5496 | 0.2% | 8.46 | 2.37–30.29 | 0.001 |
c.444 + 1G > A | 1 | 165 | 0.6% | 22 | 5496 | 0.4% | 1.52 | 0.20–11.32 | 0.68 | |
del5395 (ex10-11del) | 1 | 165 | 0.6% | 24 | 5496 | 0.4% | 1.39 | 0.19–10.34 | 0.75 | |
CHEK2 truncating | 5 | 165 | 3.0% | 58 | 5496 | 1.1% | 2.93 | 1.16–7.40 | 0.02 | |
c.470C > T | 9 | 165 | 5.5% | 264 | 5496 | 4.8% | 1.28 | 0.59–2.17 | 0.84 | |
Any CHEK2 | 14 | 165 | 8.5% | 321 | 5496 | 5.8% | 1.45 | 0.87–2.42 | 0.21 | |
NBN | c.657_661delACAAA | 1 | 165 | 0.6% | 22 | 4000 | 0.55% | 1.10 | 0.15–8.23 | 0.92 |